Business
Franchise hits keep falling flat, weighing on box office

Moviegoers will find a wealth of familiar franchises on the big screen this year. It may not be enough to save the box office.
New entrants from popular film series dominate the movie slate in the next 12 months. The 2026 schedule features releases from Star Wars, Marvel, DC Comics, Toy Story, Super Mario Bros., Hunger Games, Scream, Scary Movie, Minions, Dune and Jumanji.
Intellectual property like these established franchises has long been an important part of Hollywood, but they are increasingly vital in 2026 as the theatrical industry seeks to break the $10 billion mark at the domestic box office for the first time since the pandemic.
But some big-name installments aren’t drawing the crowds they used to, and industry insiders worry the $10 billion benchmark may be beyond reach this year for a post-pandemic industry that has been rocked by production shutdowns, the consolidation of major studios and a shift in consumer viewing toward streaming.
“The reliance on franchises has been a little trickier the last few years,” said Alicia Reese, senior vice president of equity research for Wedbush. “Yes, there’s a level of certainty … but it’s not a home run. It’s never going to be a home run from here on out, because people are pickier than they used to be. They know what’s coming. Word of mouth means more than ever.”
Since 2010, the top 10 highest-grossing films domestically have predominantly been franchise films, according to data from Comscore. During that time, between eight and 10 of the films released each year were a sequel, prequel or remake. The only outlier was 2020, when seven of the top 10 films were franchise-based, due to the number of films that were delayed during Covid shutdowns.
And, of course, a number of the original titles that broke into the top 10 have become franchises themselves in the last two decades. Look at “Avatar,” “Frozen,” “Zootopia,” “Inside Out,” “Secret Life of Pets” and “Ted.”
“Studios clearly feel that audience comfortability — with going to see a movie where they already, in some sense, know what they’re getting before they walk into the auditorium — is a bet worth making,” said Paul Dergarabedian, head of marketplace trends at Comscore.
As studios lean into the safety of a built-in audience, box office sales become more reliant on the success of these franchise films.
Prior to the pandemic, during the span of 2010 to 2019, top 10 films represented an average of 30% of the total domestic box office annually. Outpacing the group was the 2019 calendar where these films accounted for nearly 40% of the annual haul. All 10 films that year were IP-driven, and nine of them generated more than $1 billion globally.
Post-pandemic, the average percentage that the top 10 films represent of the total annual domestic box office is 44%.
“I remember having this conversation the late ’90s,” said Eric Handler, managing director and senior research analyst at Roth Capital Partners. “The box office has for the last several decades been franchise-driven. That’s just the way it is. Why? It’s because when there’s familiarity with content, there’s a greater chance that people will show up because there’s an affinity towards a particular franchise and it’s already known.”
Now, Hollywood is facing the harsh reality of what happens when franchises fall flat.
Great expectations
Two of the most anticipated films to hit theaters last year — Universal’s “Wicked: For Good” and Disney’s “Avatar: Fire and Ash” — underperformed expectations.
The first “Wicked” movie, released in 2024, tallied $475 million at the domestical box office and a little more than $750 million globally during its run in theaters. A year later, the second part of the duology collected just under $350 million from the U.S. and Canada and about $525 million globally.
Box office analysts attributed the smaller ticket sales to a drop in quality between the first and second installments. “Wicked” generated an 88% “Fresh” rating on review aggregator Rotten Tomatoes, while “Wicked: For Good” scored a 66% rating.
“Avatar: Fire and Ash” had even bigger shoes to fill. James Cameron’s breakout hit “Avatar,” released in 2009, snared $785.2 million domestically and $2.1 billion internationally. It remains the highest-grossing film of all-time at the box office with $2.9 billion in ticket sales.
More than a decade later, “Avatar: The Way of Water” hit theaters, generating $688.8 million domestically and $1.6 billion internationally, bringing its total haul to $2.3 billion.
But when “Fire and Ash” hit theaters in December, consumer demand wasn’t nearly as high and the allure of Cameron’s ground-breaking filming techniques had worn off. “Fire and Ash,” which is still playing in theaters, has tallied just $378.5 million domestically and passed $1 billion internationally as of Sunday.
Wedbush’s Reese said part of the problem can be trying to mine too much from any one franchise.
Take, for example, Disney’s Marvel Cinematic Universe. The film franchise has been a box office darling for nearly two decades, but struggled in the wake of the climactic “Avengers: Endgame” in 2019 to produce consistent quality sequels. At the same time, it flooded the streaming market with a dozen new television series.
“If you try to stretch it too thin and you don’t put the same level of attention to details that it’s not going to work,” Reese said.
There’s also risk in trying to broaden a niche interest into a global success, she said. Do filmmakers stay close to the original IP and play to its base, or do they shoot for a wider audience and a bigger splash?
Sandworms emerge on the desert planet Arrakis in Denis Villeneuve’s “Dune: Part Two.”
Warner Bros. | Legendary Entertainment
Reese noted Warner Bros.’ new Dune franchise, starring Timothée Chalamet and directed by Denis Villeneuve, is a good example of a series that’s threaded the needle, landing with fans who already loved the books at the same time that it drew in new crowds.
“If it’s a good film, it’ll service that core audience and it might bring in some newbies and have that broader appeal,” Reese said. “But, if you try to get that broad appeal and you’re not servicing your core fans, they will turn against you. That will spell huge problems, because if they don’t like the film, everyone else is going to find out about it, and they won’t go either, right?”
More than a film
Since Covid shutdowns all but decimated the movie industry in early 2020, the number of films being produced for theatrical release has declined.
As studios produce fewer films, they’re counting even more on what they perceive as the safe bets of tried and true IP.
In 2024, 94 movies were released in more than 2,000 locations, a 20% decline from the 120 wide releases in 2019. That decline was mirrored in the box office results, which were down about 23% from the $11.4 billion tallied in 2019.
In 2025, there were 112 wide released films, about 6.6% down from 2019 levels, but the box office still lagged more than 20%.
Hollywood analysts point to several factors to explain why the domestic box office continues to drag.
There is a lack of theatrical content, particularly films that are in the mid-budget range — $15 million to $90 million. Most of these films, which tend to be dramas, comedies, romantic comedies and thrillers, have transitioned to streaming, as they are cheaper to make and help pad digital libraries with new content.
At the same time, consumers have become pickier about what they watch and the home entertainment space has advanced in a way that in-home technology makes staying on the couch easier.
Because of this, studios and theater owners have started “eventizing” film releases — promoting the films as must-see in premium large format theaters like IMAX, Dolby Cinema, Screen X or 4DX; selling specialty merchandise like popcorn buckets and drink sippers as well as limited-time food options; and hosting events associated with a film release like friendship bracelet making for the Taylor Swift concert film release.
Often, the films that are easiest to promote in this way are those that are based on known franchises.
Last year, when “Downton Abbey: The Grand Finale” hit theaters, Alamo Drafthouse hosted fancy dress screenings, encouraging moviegoers to arrive in period-appropriate attire. The event included a costume contest and themed drinks and food. The theater chain has hosted similar events for screenings of James Bond and Star Wars films and will host one for the upcoming “Wuthering Heights” adaptation.
And these franchises aren’t just showing up in movie theaters. Many major film studios also have their own consumer product and experience divisions, which rely on theatrical content to not only sell merchandise but fuel theme park designs, live events and even cruise ships.
Fans of franchises are hungry for products that celebrate and show off their favorite characters or movie moments. This can manifest in the form of apparel, bedding, kitchen utensils and bumper stickers all the way to collectibles, luxury watches, electronics and seasonal products like ornaments.
Disney has built theme park lands, rides and cruise ship elements based on Star Wars, Marvel, The Muppets, Pixar films like Cars, The Incredibles, Toy Story and Monsters Inc., as well as Disney Animation properties like Frozen, Zootopia, Moana, The Lion King and the Little Mermaid.
New Toy Story Land at Disney’s Hollywood Studio
Source: Courtesy Visit Orlando
Comcast’s Universal, too, has decked out its theme parks with its own properties — Jurassic Park, Minions, Secret Life of Pets, Dark Universe and How to Train Your Dragon — alongside licensed franchises like the Wizarding World of Harry Potter and Nintendo.
And beloved and well-tended-to franchises have staying power: The Star Wars franchise hasn’t notched a new theatrical release since 2019, yet it’s remained one of the top film franchises in the cultural zeitgeist, according to Fandom, the world’s largest platform for entertainment fans.
Disclosure: CNBC and Rotten Tomatoes are divisions of Versant Media.
Business
McDonald’s (MCD) Q4 2025 earnings
A McDonald’s cheeseburger, fries, and soda arranged in Celina, Texas, US, on Tuesday, Sept. 2, 2025.
Jake Dockins | Bloomberg | Getty Images
McDonald’s is expected to report its fourth-quarter earnings after the bell on Wednesday.
Here’s what Wall Street analysts surveyed by LSEG are expecting the company to report:
- Earnings per share: $3.05 expected
- Revenue: $6.84 billion expected
The fast-food giant, often viewed as a bellwether of consumer spending, has been warning for more than a year that low-income consumers are spending less. In response, McDonald’s has embraced discounted offerings, from rolling out a value menu to relaunching Extra Value combo meals.
One bright spot for McDonald’s and the broader fast-food segment has been high-income diners, who are trading down from fast-casual restaurant options. Buzzy promotions have won over those consumers and boosted the chain’s sales, too; the fourth quarter included the return of Monopoly, as well as the Grinch meal, timed for the holiday season.
Analysts are projecting that McDonald’s same-store sales will rise 3.9%, fueled by a 5.4% increase in the U.S., according to StreetAccount estimates.
Despite the rebound in its sales, McDonald’s shares have risen only about 4% over the last year, hurt by broader concerns about the consumer and the rise of GLP-1 drugs.
Business
M2 Ingredients opens innovation center

Center will accelerate functional mushroom product development.
Business
Lloyds Banking Group to close another 95 branches
The closures have been announced days after Santander said it would shut branches.
Business
Instagram head questioned in social media addiction trial
Instagram’s longtime lead Adam Mosseri arrived on Wednesday at a courtroom in Los Angeles.
Business
Fiberstar, Inc. adds acacia gum alternative

Citri-Fi Pro may replace up to 75% of acacia gum in beverages.
Business
Prediction markets head into basketball season after Super Bowl high
A basketball finds nothing but net during practice before a 2024 NCAA Tournament game at PPG Paints Arena in Pittsburgh.
Charles LeClaire | Reuters
Prediction markets saw strong results from the Super Bowl, but it was just an appetizer for a banquet of sporting events in 2026 that are expected to drive surging volumes in event contracts.
Kalshi saw record downloads during Super Bowl week, up 1,544% from the same time period last year, according to a report from market intelligence firm Sensor Tower. Daily active users jumped more than 1,100% to nearly 2 million on the day of the big game, the firm said.
That was almost three times the daily active users on sportsbook BetMGM, co-owned by MGM and Entain, which had 81% growth to 680,000 daily active users. Polymarket reported 59,000 daily active users and 264% growth over the previous year.
More than $1 billion was traded on Kalshi for the Super Bowl, up 2,700% according to the company. Founder and CEO Tarek Mansour told CNBC Tuesday that consumers are drawn by having lots of trading options for the game in one place.
“Our culture markets were huge this weekend. You know, ‘What [Bad] Bunny was going to perform’ was over $100 million in trading,” he said.
Though prediction markets enable users to buy event contracts for a wide swath of financial, weather, pop culture and other events, sports have been driving the action and the profits.
Robinhood CEO Vlad Tenev is pushing back against any investor concerns the Super Bowl was as good as it gets for trading on sports prediction markets.
“What we’re actually seeing is surprising us,” Tenev said on his company’s fourth-quarter earnings call on Tuesday. “In January, for instance, NBA contracts surpassed NFL in trading activity on our platform.”
Major sports events keep rolling, with the Winter Olympics offering a variety of betting options through Feb. 22. This weekend, fans will also get an eyeful during the NBA All-Star Weekend.
March brings college basketball madness, with the NCAA Tournament taking off with Selection Sunday on March 15. The entire tournament typically brings in more gambling dollars than Super Bowl.
And then there’s the World Cup, kicking off 104 games in mid-June.
Kalshi has been aggressive in marketing, outspending Polymarket in the United States by about 19 times and outspending DraftKings by about 35%, according to Sensor Tower estimates.
Still, the American giants in sports betting remain dominant. DraftKings saw 5 million daily active users for the Super Bowl and FanDuel had 4.2 million, according to the Sensor Tower data.
The CEOs of sportsbook market leaders FanDuel and DraftKings both told CNBC just before the game that they don’t see any cannibalization of their traditional sports betting business. They instead see real opportunity with sports and event contracts in states that haven’t legalized sports wagering.
Tenev said events contracts are the “fastest growing business in the company’s history.” Robinhood reported a 300% rise in “other revenue,” which is largely comprised of event contracts.
And the growth is accelerating. Robinhood reported 12 billion event contracts in 2025, and it’s already seen 4 billion contracts so far in 2026.
Disclosure: CNBC and Kalshi have a commercial relationship that includes a minority investment.
Business
Changing colors without sapping demand

Meeting the challenges of switching to colors perceived as natural.
Business
Amazon to expand same-day prescription delivery to 4,500 US cities by 2026
Payne Capital Management President Ryan Payne explains why tech earnings remain strong despite a recent dip and how AI hiring could help offset a wave of baby boomer retirements on ‘Mornings with Maria’.
Amazon is expanding its same-day prescription delivery service to nearly 4,500 U.S. cities and towns by the end of 2026, adding about 2,000 new communities, including statewide coverage in Idaho and Massachusetts.
The move deepens Amazon’s push into the prescription drug market, which it entered in 2018 through its acquisition of PillPack. The company is positioning faster delivery and subscription pricing as competitive advantages against traditional pharmacy chains.
Amazon said the expansion comes as pharmacy closures, staffing shortages and transportation barriers make it harder for some patients – particularly in rural and remote areas – to access medications.
AMAZON TO CUT 16,000 ROLES AS IT LOOKS TO INVEST IN AI, REMOVE ‘BUREAUCRACY’
“Patients shouldn’t have to choose between speed, cost, and convenience when it comes to their medication, regardless of where they live,” said John Love, vice president of Amazon Pharmacy. “By combining our pharmacy expertise with our logistics network, we’re removing critical barriers and helping patients start treatment faster—setting a new standard for accessible, digital-forward pharmacy care.”

Boxes lie on a conveyor belt during Cyber Monday at Amazon’s fulfillment center in Robbinsville, New Jersey, U.S., Dec. 2, 2024. (Eduardo Munoz/Reuters)
The company said it improved delivery speeds across all 50 states and Washington, D.C., in 2025. Faster shipping is expanding into rural areas, including remote Alaska towns and parts of the Navajo Nation, where the nearest pharmacy can be nearly an hour away.
AMAZON SPEEDS UP PRESCRIPTION DELIVERY IN NYC, LA

Close-up of an Amazon Pharmacy shipping label on a cardboard box, Reliez Valley, California, Feb. 9, 2025. (Smith Collection/Gado/Getty Images)
Amazon is also integrating pharmacy services with One Medical, the primary care provider it acquired in 2023. Some One Medical patients can pick up prescriptions at in-clinic kiosks, and the company began filling select prescriptions at those electronic kiosks in December. One Medical operates on a $199 annual membership model.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| AMZN | AMAZON.COM INC. | 203.29 | -3.67 | -1.77% |
In October, Amazon partnered with WeightWatchers to supply medications, including injectable GLP-1 obesity treatments, to its members. Amazon Pharmacy also offers the oral GLP-1 Wegovy pill.

Amazon packages seen on a conveyor belt at a warehouse facility. (Luke Sharrett/Bloomberg via Getty Images / Getty Images)
The company continues to promote cost-saving programs, including Prime Rx discounts of up to 80% on generics and 40% on brand-name drugs for uninsured members, as well as RxPass, a $5-per-month subscription available in 48 states for more than 50 common medications.
CLICK HERE TO GET FOX BUSINESS ON THE GO
Amazon said its expanded same-day and next-day delivery network is aimed at patients managing both acute and chronic conditions.
Reuters contributed to this report.
Business
Drugmaker warns copycat GLP-1 drugs pose serious safety risks to patients
Novo Nordisk President and CEO Mike Doustdar joins ‘Mornings with Maria’ to discuss the launch of the first GLP-1 weight-loss pill in the U.S., the lawsuit against Hims & Hers and talks with the Trump administration on drug pricing.
GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety.
“When you go and try to source raw materials from China or unknown sources, put it in an injection, and sell knockoff medication, there is something wrong with this,” Mike Doustdar, president and CEO of Novo Nordisk, told FOX Business’ Maria Bartiromo.
Novo, best known for its blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy, has filed a lawsuit against Hims & Hers Health, accusing the telehealth company of selling compounded, unapproved versions of its semaglutide-based medications, including a copycat version of its newly launched daily pill.
Doustdar said the introduction of the oral option broadens access for patients who are reluctant to use injections, but he sharply criticized what he described as widespread “mass compounding” of GLP-1 drugs by telehealth firms.
DANGEROUS ‘GRAY-MARKET’ WEIGHT-LOSS DRUGS FLOODING US AS EXPERTS WARN OF RISKS

A woman injects a GLP-1 injection into her stomach in this undated photo taken at an undisclosed location. (iStock / iStock)
“Compounding is supposed to be for a few individuals that have, let’s say, allergic reactions to the real medicine,” he said. “But this mass compounding — it’s quite unbelievable that it has gotten to this point.”
He added that Novo has filed multiple lawsuits against compounders, arguing that the launch of a compounded pill version crossed a line.
“I think the nail in the coffin, as they say, was when they completely made a new drug — the pill — a compounded version of it and basically tried to introduce that to the market,” he said. “That’s where we felt enough is enough.”
TARGET BEEFS UP PROTEIN, SUPPLEMENT OFFERINGS, CAPITALIZING ON WEIGHT LOSS DRUG TREND

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah on Thursday, Jan. 15. (George Frey/Bloomberg via Getty Images / Getty Images)
Hims & Hers fired back against Novo Nordisk in a statement issued to multiple outlets this week, blasting the legal move as “a blatant attack by a Danish company on millions of Americans who rely on compounded medications for access to personalized care” and accusing “Big Pharma” of “weaponizing the U.S. judicial system to limit consumer choice.”
“This lawsuit attacks more than just one medication or company – it directly assaults a well-established, vital component of U.S. pharmacy practice that has improved patient care for everything from obesity to infertility to cancer,” a representative for the company said, per the New Jersey business publication NJBIZ.
The company also cited its history of providing “safe access to personalized healthcare to millions of Americans,” adding that it will “continue to fight to provide choice, affordability and access.”
AIRLINES HAVE 580 MILLION REASONS TO LIKE GLP-1 WEIGHT-LOSS DRUGS, ANALYSIS FINDS

The New York Stock Exchange with a Hims & Hers Health, Inc. banner is pictured as a person runs past in the Manhattan borough of New York City, New York on Jan. 21, 2021 (Reuters/Carlo Allegri / Reuters)
For some time, patients seeking GLP-1 therapy for conditions such as obesity, type 2 diabetes, fatty liver disease and metabolic syndrome have sought compounded alternatives after facing insurance roadblocks that created cost challenges for brand-name medications.
Doustdar said Novo’s recent cost reductions have eliminated the need for copycat drugs due to what he described as pricing similarities between branded and compounded versions.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Fox News senior medical analyst Dr. Marc Siegel joins ‘Mornings with Maria’ to break down the new FDA-approved weight loss pill, concerns over cost and safety and how GLP-1 drugs could transform obesity care.
However, when Hims & Hers briefly launched its compounded oral semaglutide, it was marketed at about $49 per month as an introductory price and around $99 per month thereafter, lower than Novo’s FDA-approved oral Wegovy, which launched at roughly $149 per month and can cost up to $299 at higher doses under self-pay pricing.
Hims & Hers later pulled the oral compounded medication from its platform following legal threats from Novo and scrutiny from federal regulators.
Business
Medicare coverage opens 15 million-patient opportunity

Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year.
Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people would be a good number to target,” he told CNBC in an interview.
Medicare is slated to start covering obesity medicines for the first time later this year under the landmark “most favored nation” drug pricing deals that Novo and its chief rival Eli Lilly struck with President Donald Trump in November.
Health experts say the long-awaited coverage could broaden the market for the medicines and spur more private insurers to cover them. Some experts estimate that 20 million to 30 million Medicare patients are suffering from obesity and related conditions.
Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following that agreement with Trump.
But he said he doesn’t expect Medicare access to obesity treatments to open up overnight.
“Now, it would be great if we could find a way to get access very, very fast. But I think that would be a bit naive,” Doustdar said, pointing to the slow adoption seen among eligible patients with commercial insurance.
It’s a slightly more conservative tone on the initial impact of Medicare coverage compared to Lilly, which has cited that coverage as a key tailwind to its guidance this year. Last week, Lilly said it expects Medicare coverage to come online by July.
Meanwhile, Doustdar said Novo is in the midst of negotiations with the government on “exactly which month, which week that is going to be opening.”
Closing the market share gap
Novo is under pressure to claw back market share in the booming GLP-1 space from Lilly and cheaper, compounded copycats. Last week, Lilly said its share of the U.S. obesity and diabetes drug market increased to 60.5% in the fourth quarter, while Novo’s was 39.1%.
Novo has also highlighted a gap in the “preference share” for its weight loss treatment Wegovy versus Lilly’s rival injections. In the U.S., Novo estimates that between 7 and 8 patients out of 10 go to Lilly.
When asked how Novo plans to close that gap, Doustdar said one way to do so is “to do better on the pill.” The company’s Wegovy obesity pill has a head start compared to Lilly’s upcoming oral drug, orforglipron, which is expected to win approval from the Food and Drug Administration during the second quarter.
Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
Doustdar said Novo’s pill is slightly more effective than Lilly’s based on separate clinical trials, showing 16.6% weight loss compared to 12.4% with Lilly’s oral drug.
“If you use these two numbers, basically you have a 40% difference between the efficacy of these pills,” he said. “I think this is going to be a very main, main selling point of the pill.”
But Doustdar also pointed to the upcoming approval and launch of a higher dose – 7.2 milligram – of Wegovy that could help win market share from Lilly’s obesity treatment Zepbound.
That higher dose helps patients lose around 21% of their weight, which is “very much on par” with the highest dose of Zepbound, he said. Zepbound’s higher efficacy has been a key factor in driving more patients and prescribers away from choosing Wegovy, which has shown around 15% weight loss on average in clinical trials.
“When that comes to the market, my thought, my wish, my hope is that people will realize, OK, now we have two products with similar efficacy,” he said.
-
Politics3 days agoWhy Israel is blocking foreign journalists from entering
-
Sports5 days agoJD Vance booed as Team USA enters Winter Olympics opening ceremony
-
NewsBeat2 days agoMia Brookes misses out on Winter Olympics medal in snowboard big air
-
Business3 days agoLLP registrations cross 10,000 mark for first time in Jan
-
Tech5 days agoFirst multi-coronavirus vaccine enters human testing, built on UW Medicine technology
-
Tech15 hours agoSpaceX’s mighty Starship rocket enters final testing for 12th flight
-
NewsBeat3 days agoWinter Olympics 2026: Team GB’s Mia Brookes through to snowboard big air final, and curling pair beat Italy
-
Sports3 days agoBenjamin Karl strips clothes celebrating snowboard gold medal at Olympics
-
Sports4 days ago
Former Viking Enters Hall of Fame
-
Politics3 days agoThe Health Dangers Of Browning Your Food
-
Sports5 days ago
New and Huge Defender Enter Vikings’ Mock Draft Orbit
-
Business3 days agoJulius Baer CEO calls for Swiss public register of rogue bankers to protect reputation
-
NewsBeat5 days agoSavannah Guthrie’s mother’s blood was found on porch of home, police confirm as search enters sixth day: Live
-
Business3 days agoCostco introduces fresh batch of new bakery and frozen foods: report
-
Business6 days agoQuiz enters administration for third time
-
Crypto World1 day agoBlockchain.com wins UK registration nearly four years after abandoning FCA process
-
Crypto World1 day agoU.S. BTC ETFs register back-to-back inflows for first time in a month
-
NewsBeat2 days agoResidents say city high street with ‘boarded up’ shops ‘could be better’
-
Sports2 days ago
Kirk Cousins Officially Enters the Vikings’ Offseason Puzzle
-
Crypto World1 day agoEthereum Enters Capitulation Zone as MVRV Turns Negative: Bottom Near?
